Capsida Biotherapeutics granted orphan drug designation for potential gene therapy for STXBP1-related disorders
FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy
Advancing Toward Gene Therapies for Rare Epilepsies
Newly Published “Voice of the Patient Report”
STXBP1 Census - Q3 2024
Six patient advocacy groups collaborate to co-fund a single-center observational study of seizure types in rare genetic epilepsies
NPR Stateside Podcast: One family's fight to find a cure for daughter's rare genetic disorder
Glowing reviews for STXBP1-Related Disorders Research
The STXBP1 Foundation and Children’s Hospital of Philadelphia Announce Phase 2 of the STARR Study for Clinical Trial Readiness, and Clinic Expansion